NVO. Pays a good dividend. And should continue to grow earnings at an acceptable rate with their new drug pipeline (cagrisema, amycretin). Ozempic also continues to get one more new indication after the other (kind of how ACE-Inhibitors are used to treat kidney disease in diabetics that may not necessarily have hypertension).